Lab 21 is now offering a comprehensive lung and colon panel that covers the following 22 genes.
This test offers advantages over single test genes utilising targeted next generation sequencing.
- It is quicker and cheaper to conduct a single multi-gene test than multiple sequential single-gene tests.
- Multiple genes can be tested from a single biopsy within one laboratory analysis. Less DNA/tissue is used in a multi-gene panel as compared to multiple single-gene tests; this is particularly pertinent to disease sub-types where tissue is limited.
- NGS provides information regarding the relative frequency with which a mutation is found within a single biopsy; in turn, this information can be used to help inform clinical trial outcome data.
- As new genes are identified that are implicated in cancer, these can be added to NGS panels relatively quickly.
- Multi-gene panel testing is increasingly required to guide patient selection to clinical trials, providing clinicians with more treatment options to offer their patients.
- Increasing evidence suggests that there can be multiple ‘driver genes’ operating within tumour genomes at any one time, therefore a comprehensive analysis of known ‘drivers’ are included in the gene panel to allow clinicians to make more informed and rational decisions about standard of care treatment for their patients or to determine whether individual patients may be suitable for therapies available in one or more clinical trials. For example, mutations in KRAS, EGFR, BRAF, PIK3CA, PTEN, AKT1 occur at different frequencies in non-small cell lung cancer (NSCLC), conducting parallel or sequential single-gene tests for each of these genes would exhaust valuable tissue and have cost and/or time implications.
Although the absolute sensitivity of our targeted NGS approach will vary from sample to sample depending upon variables such as tumour content and the quality/quantity of DNA extracted from any supplied material, overall sensitivity and specificity on any given sample has been demonstrated to be at least as good as traditional single gene tests, and in many cases will be significantly higher.
Furthermore the assay is not constrained by the detection of only a limited subset of the most common variants as in the case of most single gene tests. Rare and novels variants can be detected with the same sensitivity as previously well characterised ones.
Information for test processing
To request Comprehensive 22 gene Lung & Colon panel test, the first point of contact is the dedicated Lab 21 Customer Services Team who handle:
- Test Requests and Customer Support
- Liaison with Sample Retention Sites for sample retrieval if required
- Reporting of the results
Not provided under our UKAS accreditation.
Please see our Accreditation page for full scope of accredited testing.
Fixed tissue (including FNA, resection specimen, core biopsy etc.): One (1) formalin-fixed paraffin-embedded (FFPE) block from a biopsy or surgical resection should be provided. The combined area of tumour tissue (not total tissue) must be a minimum area of 4mm².